We describe a patient with bcr/abl-positive acute mixed lineage leukemia who successfully underwent transplantation in primary induction failure, using unmanipulated bone marrow from a human leukocyte antigen (HLA)-haploidentical cousin. The tumor burden was successfully reduced by the administration of imatinib mesylate (STI571) before transplantation. As graft-versus-host disease (GVHD) prophylaxis, a combination of tacrolimus and a short course of methotrexate, methylprednisolone, and mycophenolate mofetil was used. Hematopoietic reconstitution was rapid, and acute GVHD was limited to the skin (grade I). The patient is still in complete remission past day +400. This successful case suggests that HLA-haploidentical transplantation using unmanipulated marrow from a distantly related relative can be considered for patients in urgent situations who do not have HLA-identical donors. Bone Marrow Transplantation (2003) 31, 1165-1168. doi:10.1038/sj.bmt.1704064 Keywords: HLA-mismatched BMT; graft-versus-host disease; bcr-abl-positive acute leukemia; imatinib Allogeneic stem cell transplantation (SCT) remains the only curative treatment option for patients with advanced hematologic malignancies. In patients with chemoresistant relapse, who do not have human leukocyte antigen (HLA)-identical related donors, a time-consuming search for a closely HLA-matched unrelated donor is not practical. In such cases, SCT from an HLA-mismatched related donor has been carried out as an alternative option. Recently, it was reported that haploidentical HLA 3-loci mismatched SCT was performed using T-cell-depleted 1 and/or CD34-positive selected stem cells. 2 This method has some difficulties, namely, increased risks of life-threatening infection and relapse after transplantation.
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We recently reported an intensive acute graft-versus-host disease (GVHD) prophylactic regimen consisting of tacrolimus (FK506), methotrexate (MTX), and methylprednisolone (mPSL), which resulted in almost complete suppression of acute GVHD in unrelated bone marrow transplantation (BMT). 4 Next, we designed a novel GVHD prophylaxis regimen by adding mycophenolate mofetil (MMF) to this three-drug regimen, used it with HLAmismatched SCT using unmanipulated marrow from related donors, and demonstrated that the regimen was able to successfully control GVHD after transplantation from an HLA-haploidentical (3-antigen-mismatched) sibling donor. 5 In that case, hematopoietic engraftment after transplantation was rapid, with minimal transplant-related toxicity. Furthermore, a remarkable graft-versus-leukemia effect was observed, although the patient underwent transplantation in resistant relapse. The patient remains in molecular complete remission (CR) past day +600.
Based on these findings, we then explored the possibility of extending the range of donor candidates to cousins using the four-drug regimen for GVHD prophylaxis. Here we report a successful case of haploidentical (3-antigenmismatched) transplantation using unmanipulated marrow from a cousin, for bcr/abl-positive acute mixed lineage leukemia (AMxL). ). Cytogenetic analysis showed a complex karyotype (46, XX, der(2) t(2;12) (q33;q11), add(4) (q11), add(6) (p21), add(7) (q11), add(9) (q34),-12, add(16) (p11), der(17) add(17) (p13) add(17) (q21), -22).
Case report
In bcr/abl-specific fluorescence in situ hybridization (FISH) analysis of the bone marrow cells, 92.2% of the cells were positive. Both major and minor bcr/abl chimeric mRNAs were detected by reverse transcriptase-polymerase chain reaction (RT-PCR) analysis. The white blood cell (WBC) count was 190 Â 10 9 /l (blasts 66%) at diagnosis. The patient initially received chemotherapy targeting myeloid leukemia cells consisting of idarubicin (IDR), cytosine arabinoside (Ara-C), vincristine (VCR), and prednisone (PSL). Blasts in the peripheral blood (PB) were thereby decreased to 5% (WBC count, 0.4 Â 10 9 /l), but then increased to 91% (WBC count, 18 Â 10 9 /l) 1 week later. The patient then received treatment targeting lymphoid leukemia cells using the JALSG ALL-97 protocol, consisting of cyclophosphamide (CY), daunorubicin (DNR), VCR, PSL, and l-asparaginase (l-Asp). Blasts again decreased to 1% (WBC count, 0.3 Â 10 9 /l), but again increased to 89% (WBC count, 13 Â 10 9 /l) after a few weeks (Figure 1 ). Therefore, imatinib mesylate (STI571) (Gleevec, Novartis, Basel, Switzerland) 400 mg daily in addition to a high dose of Ara-C, mitoxantrone, etoposide, and PSL were given as salvage chemotherapy. Blasts disappeared from the PB, but imatinib alone was continued until transplantation (for a total of 33 days) to suppress regrowth of blasts.
The patient was transferred to our hospital to undergo allogeneic SCT. Since there was no time to locate an unrelated donor, we searched for a donor candidate in her family. The HLA profiles of the patient and her relatives are shown in Figure 2 . The patient had no HLA-identical donor in her family. We decided to perform SCT from one of her cousins because her parents were too old to donate bone marrow (BM). Institutional review board approval was obtained for the treatment protocol, and written informed consent was obtained from the patient and her family members, including the donor.
The clinical course is shown in Figure 1 . Immediately before the start of the conditioning, the percentage of blasts in the BM was 1%, but neutropenia (less than 0.5 Â 10 9 /l) continued. The conditioning regimen consisted of Ara-C 2 g/m 2 Â 2 on day À8 and 2 g/m 2 on days À7 and À6 (total dose 8 g/m 2 ), CY 60 mg/kg on days À7 and À6 (total dose 120 mg/kg), and fractionated total body irradiation (TBI) (12 Gy in four fractions on days À3 to À1). Imatinib was discontinued on day À3. GVHD prophylaxis consisted of a continuous intravenous infusion of FK506 (the target blood concentration was 15-18 ng/ml) from day À2, a short course of MTX 10 mg/m 2 on day +1 and 7 mg/m 2 on day +3, mPSL 2 mg/kg divided in two doses daily from day +1, and oral MMF 15 mg/kg/day daily from day +5. The patient received BM containing 3.3 Â 10 8 nucleated cells/kg (including 5.3 Â 10 6 CD34 + cells/kg) without any manipulation. Granulocyte colony-stimulating factor (lenograstim) 200 mg/m 2 /day was started from day +5. This protocol was well tolerated. Hematopoietic reconstitution was rapid, with an absolute neutrophil count 40.5 Â 10 9 /l on day +13, and platelet count 450 Â 10 9 /l on day +28. BM analysis on day +17 revealed that the patient had achieved CR. Complete donor chimerism was confirmed in the cell lineages of both CD3 + cells and granulocytes in the PB based on PCR-based analysis of variable numbers of tandem repeats. Since cytomegalovirus (CMV) antigenemia occurred on day +35, the patient received foscarnet, which effectively controlled the CMV antigenemia, as indicated by the disappearance of CMV antigen-positive leukocytes on day +70. Histologically proven acute GVHD of the skin occurred on the extremities on day +50 (grade I), but subsided with no increase in the dose of immunosuppres- HLA-haploidentical transplantation from a cousin K Ikegame et al sive agents. The skin rash recurred on day +80, but was controlled by slightly increasing the doses of immunosuppressive drugs. The BM was examined frequently to monitor minimal residual disease by quantitating gene expression of the bcr/abl chimeric gene or the Wilms' tumor gene 6 by RT-PCR, bcr/abl-specific FISH analysis, and CD45-blast gating flow cytometry, and the results of all of these analyses demonstrated continuing CR. PSL and FK506 were tapered to 30 and 2 mg/day, respectively, on day +112, when the patient was discharged with 100% Karnofsky performance status. On day +400, when we submitted this manuscript, the patient was still in molecular remission with no sign of chronic GVHD, receiving a low dose of immunosuppressive agents (FK506 2.0 mg/day and PSL 13 mg/day).
Discussion
Patients with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) have been reported to have a lower probability of leukemia-free survival following allogeneic BMT than those with Ph-negative ALL. 7 In addition, only a minority of patients with primary refractory acute leukemia experience long-term survival following allogeneic SCT. 8 Recently, imatinib, a selective inhibitor of bcr/abl tyrosine kinase, has been used for the treatment for bcr/abl-positive leukemia. In the present case of primary induction failure, imatinib, coupled with conventional chemotherapy, very effectively reduced the leukemia burden before transplantation without causing any organ impairment. Consequently, we consider that the low tumor burden at transplantation contributed to the long-term disease-free survival following allogeneic SCT. The median time to progression has been reported to be 2.2 months in relapsed or refractory Ph-positive ALL patients who achieved CR by the use of imatinib. 9 Considering that leukemic blasts easily acquire drug resistance, and that immunotherapy is more effective when the tumor burden is low, the use of imatinib to reduce the leukemia burden before allogeneic transplantation may be a promising therapeutic procedure. In T-cell-depleted BMT, the Perugia group reported that stem cell dose was important in transplant outcome. 2 However, in non-T-cell-depleted BMT, infusing large numbers of CD34+ cells is considered to be unnecessary because of the infusion of sufficient T cells to obtain engraftment.
It remains unknown why the acute GVHD was mild in the present case. However, patients may be able to avoid fatal acute GVHD even in haploidentical BMT if a strong GVH reaction in the early phase of transplantation can be controlled with appropriate drugs or treatment procedures. 10 Although feto-maternal tolerance has been reported to be associated with the induction of immunological tolerance in HLA-mismatched solid organ transplantation, 11 that concept cannot explain the success of the present case. Furthermore, the severity of GVHD in HLA-haploidentical transplantation may be partially influenced by a race-dependent effect of donors and recipients. 12, 13 Since the follow-up period was too short to prove clinical efficacy in the present case, we cannot yet conclude whether unmanipulated HLA-haploidentical (3-antigen-mismatched) SCT from a distantly related relative will become a common treatment modality, but it might be considered as one of the alternative options, especially in urgent situations. HLA-haploidentical transplantation from a cousin K Ikegame et al
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